A Phase 1 Investigator And Subject-Blind Study In Healthy Subjects To Evaluate The Pharmacodynamic Effects Of Single Doses Of PF-04995274 On Sapp-Alpha Concentrations In Cerebrospinal Fluid Using Serial Sampling Methodology.
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2012
At a glance
- Drugs PF 4995274 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
- 11 Jan 2011 Planned end date changed from 1 Dec 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 11 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.